ClinicalTrials.gg
Active, not recruitingNCT06007677Updated Jul 23, 2025

A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema

A Phase 2 interventional study of STAR-0215 in Hereditary Angioedema, sponsored by Astria Therapeutics, Inc.. Active, not recruiting at 22 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by Astria Therapeutics, Inc. (part of BioCryst Pharmaceuticals) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals — 2 open to participants now, 5 under way, 4 of them phase 3. Angioedemas, Hereditary · BioCryst Pharmaceuticals.

Planned enrollment
10th of 21
56 · median 54
Started
2023
with 1 other
Phase 2
4 of 22
none open now
Registered
20th of 22
by date

Among the 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals, this one is the 10th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2023, is one of 4 in phase 2, and was the 20th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

2 of the 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals, or all of them as a file.
02

Study summary

The goal of this trial is to enable the collection of information about long-term safety and clinical activity of STAR-0215 in participants with hereditary angioedema (HAE). Participants will receive repeat doses of STAR-0215 for up to 5 years.

03

Conditions studied

  • Hereditary Angioedema

Keywords

  • HAE
  • Angioedema
  • Long-term
  • Safety
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Open to participants from STAR-0215-201 (NCT05695248) who have met one of the following conditions:

    • Completed STAR-0215-201 (follow up through 6 months after their last dose);
    • Eligible for STAR-0215-201 and entered the Run-In period but did not qualify for the Treatment Period because they did not meet the criterion for the minimum number of HAE attacks;
    • Eligible for STAR-0215-201 and entered the Run-In period but did not complete it for reasons other than not meeting the criterion for the minimum number of HAE attacks (eligibility requires consultation with the Medical Monitor); or
    • Discontinued STAR-0215-201 (for reasons other than safety) after having completed at least 84 days of trial follow-up since their last dose of STAR-0215 (eligibility requires consultation with the Medical Monitor).
  • Open to participants who are STAR-0215 naïve and were not enrolled in STAR-0215-201 (NCT05695248), have a documented diagnosis of HAE (Type 1 or Type 2).

Exclusion criteria

Exclusion Criteria:

  • Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1 inhibitor deficiency, HAE with normal C1-esterase inhibitor protein (also known as HAE Type III), idiopathic angioedema, or angioedema associated with urticaria.
  • Any exposure to angiotensin-converting enzyme inhibitors or any estrogen-containing medications with systemic absorption (such as hormonal or hormone replacement therapy) within 28 days prior to Screening
  • Any exposure to androgens (for example, stanozolol, danazol, oxandrolone, methyltestosterone, testosterone) within 7 days prior to Screening.
  • Use of therapies prescribed for the prevention of HAE attacks prior to Screening:

    • lanadelumab within 90 days
    • berotralstat within 21 days
    • all other prophylactic therapies, discuss with the Medical Monitor

Note: Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Dose Regimen 1 (Arm A): STAR-0215

    Participants will receive STAR-0215 every 3 months.

    Drug: STAR-0215

  • Experimental
    Dose Regimen 2 (Arm B): STAR-0215

    Participants will receive STAR-0215 every 6 months.

    Drug: STAR-0215

  • Experimental
    Dose Regimen 1 (Arm C): STAR-0215

    STAR-0215 will be administered as a subcutaneous injection.

    Drug: STAR-0215

  • Experimental
    Dose Regimen 3 (Arm D): STAR-0215

    STAR-0215 will be administered as a subcutaneous injection.

    Drug: STAR-0215

Interventions

  • STAR-0215 will be administered as a subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Treatment-emergent Adverse Events

    Time frame: Day 1 through study completion, an average of 6 years

Secondary outcomes

  1. Change From Baseline in Monthly HAE Attack Rate

    Time frame: Day 1, up to 5 years

  2. Severity of HAE Attacks Experienced by Participants

    All HAE attacks will be classified according to severity (mild, moderate, and severe).

    Time frame: Day 1 through up to 5 years

  3. Duration of HAE Attacks

    Duration will be reported as shorter than 12 hours, 12 to 24 hours, 24 to 48 hours, and longer than 48 hours.

    Time frame: Day 1 through up to 5 years

  4. Number of Participants Experiencing HAE Attacks Requiring On-demand Therapy

    Time frame: Day 1 through up to 5 years

  5. Time to First HAE Attack After Each Dose

    Time frame: Day 1 through up to 5 years

  6. Number of HAE Attack-free Days

    Time frame: Day 1 through up to 5 years

  7. Number of Participants Experiencing Zero HAE Attacks

    Time frame: Day 1 through up to 5 years

  8. Serum Concentration of STAR-0215

    Blood samples will be collected on dosing days to measure the serum concentration of STAR-0215.

    Time frame: Every 3 months for first 2 years, Every 6 months for next 3 years

  9. Plasma Levels of Cleaved High-molecular-weight Kininogen

    Blood samples will be collected on dosing days to measure the plasma levels of cleaved high-molecular-weight kininogen (a measure of plasma kallikrein activity).

    Time frame: Every 3 months for first 2 years, Every 6 months for next 3 years

  10. Number of Participants with Anti-drug Antibodies to STAR-0215

    Blood samples will be collected on dosing days to assess the formation of STAR-0215 anti-drug antibodies in serum.

    Time frame: Every 3 months for first 2 years, Every 6 months for next 3 years

07

Study locations

22 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Mar 2031, 90 months after the start.

Of 17 phase 2 interventional studies under Angioedemas, Hereditary, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's planned 90 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2023
First posted
Aug 23, 2023
StartActual
Sep 26, 2023
Primary completionEst.
Mar 2031
CompletionEst.
Mar 2031
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06007677
Responsible party
Sponsor
First posted
Aug 23, 2023
Start date
Sep 26, 2023
Primary completion
Mar 2031 (estimated)
Completion
Mar 2031 (estimated)
Last update
Jul 23, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Navenibart

Start the discussion